top of page
CREATING A NEW CLASS OF RECEPTOR TARGETED GENETIC MEDICINES
Selective modulation of gene targets in the disease tissue to achieve superior efficacy and safety
Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.
ABOUT US
Aro is a product-focused platform company, developing a wholly owned proprietary pipeline and a partnered pipeline of Centyrin-RNA drug conjugates to address previously intractable diseases.
OUR SCIENCE
We discover and optimize receptor-specific Centyrins and conjugate them to oligonucleotides to precisely modulate gene targets in disease tissues.
JOIN US
If you are interested in working on the cutting edge of genetic medicine and making a meaningful difference in patients' lives, come join our team!
LATEST NEWS
September 15, 2022
Aro Biotherapeutics Receives FDA Rare Pediatric Drug Designation for ABX1100 for the Treatment of Pompe Disease
August 10, 2022
Aro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100 for the Treatment of Pompe Disease
May 11, 2022
Aro Biotherapeutics to Present New Preclinical Data Highlighting the Potential of Centyrin-siRNA Conjugates for the Treatment of Pompe Disease
bottom of page